REG-Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering its biosimilar candidates AVT34 and AVT87 in the U.S. and select Asian markets. The deal carries a potential value of up to $150 million in upfront and milestone payments to Alvotech, plus supply revenues, and marks the first time Alvotech will directly commercialize products in the U.S.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.